stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Gross margin
Ascendis Pharma A/S's gross margin over the twelve months to 30 June 2026 was 91.3%, up 4.4 percentage points from fiscal 2025 (86.8%). Over the past ten years it has ranged from 54.7% (fiscal 2021) to 100.0% (fiscal 2020); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 86.8% | (1.01) |
| FY2024 | 87.8% | 4.47 |
| FY2023 | 83.4% | 7.08 |
| FY2022 | 76.3% | 21.57 |
| FY2021 | 54.7% | (45.29) |
| FY2020 | 100.0% | 0.00 |
| FY2019 | 100.0% | 0.00 |
| FY2018 | 100.0% | 0.00 |
| FY2017 | 100.0% | 0.00 |
| FY2016 | 100.0% | 0.00 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 91.9% | (1.05) |
| Mar 2026 | 92.9% | 2.61 |
| Dec 2025 | 90.3% | 0.75 |
| Sep 2025 | 89.5% | 9.44 |
| 42 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| SMMT Summit Therapeutics PLC compare | 100.0% |
| EXEL Exelixis, Inc. compare | 96.3% |
| BBIO BridgeBio Pharma, Inc. compare | 94.3% |
| ASND Ascendis Pharma A/S | 91.3% |
| JAZZ Jazz Pharmaceuticals PLC compare | 89.1% |
| INSM Insmed, Inc. compare | 84.4% |
| HALO Halozyme Therapeutics, Inc. compare | 82.3% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 77.3% |
| BNTX BioNTech SE Sponsored ADR compare | 74.6% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ASND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement